Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976820 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT00976820 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 323 participants.
The verdict
NCT00976820, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age. This Protocol Posting has been updated following the Protocol amendment 1 \& 2, September and October 2009. The sections impacted are study design, objectives and analysis methods.
Interventions
- BIOLOGICAL GSK2340274A
- BIOLOGICAL GSK2340273A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2009-10-20 |
| Est. Completion | 2011-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976820
The ClinicalTrials.gov registry entry for NCT00976820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK2340274A is the first listed.
NCT00976820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976820 about?
NCT00976820 is a clinical study titled "Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age". The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age. This Protocol Posting has been updated following the Protocol amendment 1 \& 2, September and October 2009. The ...
What is the current status of trial NCT00976820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2009-10-20. Estimated completion is 2011-03-21.
What interventions are being tested in trial NCT00976820?
The interventions under investigation include: GSK2340274A (BIOLOGICAL), GSK2340273A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00976820?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.